|Bid||85.95 x 200|
|Ask||88.84 x 100|
|Day's Range||87.15 - 88.54|
|52 Week Range||73.45 - 102.49|
|PE Ratio (TTM)||-26.22|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.
A deal with Pfizer, coupled with some likely short-seller covering, has shares headed higher for the second day in a row.
Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.